Vivalis expands r&d capacities and moves into new facility
Research teams integrated at site based in Nantes
French biopharmaceutical company Vivalis has moved its research and development teams into a new 3,300m2 facility in Saint-Herblain, Nantes.
All r&d teams are integrated onto the same site, which is adjacent to Vivalis' existing 1,500m2 cGMP bioproduction facility.
The new building houses equipment for biologics research and the construction has been designed to use 25% less energy than the current bioproduction facility completed five years ago.
With a total investment of €6.5m, the facility was financed by state and local entities (DIACT, Region Pays de Loire, Departement of Loire Atlantique and Nantes Métropole (€2.4m), bank loans (€2.5m) and Vivalis (€1.6m).
Vivalis says the new facility will enable the firm to accelerate its development projects while improving the working environment of its employees.
‘We are very pleased to move into these new facilities that give us the ability to regroup the teams that were spread over several locations following the rapid expansion of our workforce. We are very proud of being able to offer our researchers optimal conditions to conduct their research,’ said Franck Grimaud, chief executive, and Majid Mehtali, chief scientific officer, co-managers of Vivalis.
Vivalis provides cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases.